Skip to content
Try Mental Wellness – Lifestyle
Author:
Marvel Biosciences Corp.
Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours
November 10, 2026
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
October 19, 2026
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
October 8, 2026
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
October 6, 2026
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
August 5, 2026
New Autism Research to be Presented at European Purine Scientific Meeting
June 26, 2026
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
June 8, 2026